1
|
LaCasce AS, Dockter T, Ruppert A, Kostakoglu L, Schöder H, Hsi ED, Bogart JA, Cheson BD, Wagner‐Johnston ND, Abramson JS, Maddocks KJ, Leonard JP, Bartlett NL. CALGB 50801 (ALLIANCE): PET ADAPTED THERAPY IN BULKY STAGE I/II CLASSIC HODGKIN LYMPHOMA (CHL). Hematol Oncol 2021. [DOI: 10.1002/hon.72_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- A. S. LaCasce
- Dana Farber Cancer Institute Medical Oncology Boston USA
| | - T. Dockter
- Alliance Statistics and Data Center Mayo Clinic Rochester USA
| | - A. Ruppert
- Alliance Statistics and Data Center The Ohio State University Columbus USA
| | - L. Kostakoglu
- University of Virginia Radiology and Medical Imaging Charlottesville USA
| | - H. Schöder
- Memorial Sloan Kettering Cancer Institute Molecular Imaging and Therapy Service New York USA
| | - E. D. Hsi
- Wake Forest University Health Science Pathology Winston‐Salem USA
| | - J. A. Bogart
- SUNY Upstate Medical University Radiation Oncology Syracuse USA
| | - B. D. Cheson
- Lymphoma Research Foundation Scientific Advisory Board Member New York USA
| | - N. D. Wagner‐Johnston
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Oncology Baltimore USA
| | - J. S. Abramson
- Massachusetts General Hospital Cancer Center Hematology/Oncology Boston USA
| | - K. J. Maddocks
- Ohio State University Wexner Medical Center, Columbus, OH Hematology Columbus USA
| | - J. P. Leonard
- Meyer Cancer Center Weill Cornell Medical College Hematology and Medical Oncology New York USA
| | - N. L. Bartlett
- Washington University School of Medicine in St. Louis and Siteman Cancer Center Medical Oncology St. Louis USA
| |
Collapse
|
2
|
VanderWalde N, Satele D, Dockter T, Sloan J, Jagsi R, Lichtman S, Freedman R, Lafky J, Muss H, Cohen H, Jatoi A, Le-Rademacher J. MODELING ACCRUAL OF OLDER ADULTS TO CANCER CLINICAL TRIALS: (ALLIANCE A151736). J Geriatr Oncol 2019. [DOI: 10.1016/s1879-4068(19)31193-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
3
|
Moyer AM, Boughey JC, Kalari KR, Suman VJ, McLaughlin SA, Moreno-Aspitia A, Northfelt DW, Gray RJ, Sinnwell JP, Carlson EE, Dockter TJ, Jones KN, Felten SJ, Conners AL, Wieben ED, Ingle JN, Wang L, Weinshilboum RM, Visscher DW, Goetz MP. Abstract P4-04-05: Differential mRNA expression patterns in breast tumors with high vs. low quantity of stromal tumor–Infiltrating lymphocytes. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-04-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Tumor-infiltrating lymphocytes (TIL) have prognostic and potentially predictive significance in the (neo)adjuvant treatment of high-risk breast cancer. However, quantitative TIL measurement is not routinely performed. It is unclear why some tumors attract large quantities of TIL while others do not. We sought to confirm the association between TIL and pathologic complete response rate (pCR) and to further use next generation sequencing (NGS) to identify genes and gene pathways associated with the presence/absence of TIL.
Methods: We studied 140 women with high risk stage I-III breast cancer, enrolled in the Breast Cancer Genome Guided Therapy Study (BEAUTY), obtaining serial biopsies for DNA/RNA sequencing and MRI imaging to assess response to neoadjuvant chemotherapy (NAC) with taxane (+/- trastuzumab+/-pertuzumab for HER2+ disease) followed by AC or (F)EC. Diagnostic pre-NAC core needle biopsies and surgical resection specimens post-NAC were available from 110 patients. Stromal TIL were semi-quantitated on a scale of 1-4 (with 1: ≤10/hpf, 2: subtle infiltrate >10/hpf, 3: moderate infiltrate readily visible at low power magnification, 4: dense infiltrate with innumerable lymphocytes). For this analysis, low TIL was defined as scores of 1-2 vs. high defined as 3-4. Using pre-NAC biopsies, RNAseq was performed using the Illumina HiSeq2000 and the Mayo Analysis Pipeline for RNAseq (MAP-Rseq) for quality control, sequence alignment, and gene counts. The quantity of TIL was associated with transcripts across the transcriptome after conditional quantile normalization. Differentially expressed genes were obtained using EdgeR analysis, using a false discovery rate of 0.05, and pathways were evaluated using GAGE methods.
Results: The pCR and residual cancer burden (RCB)-0/I rates by stromal TIL status within each molecular subtype are presented in the table. A diverse spectrum of 1344 genes with differential expression between tumors with high vs. low stromal TIL was identified. The genes with >2.0-fold change (FC) and p<1e-09 included S100A7 (4.49 FC), LCN2 (2.48 FC), and ART3 (2.82 FC) (genes known to be involved in immune regulation), as well as TDRD1 (2.71 FC) (a gene related to ERG [ETS-related gene] expression). In addition, the "regulation of actin cytoskeleton" pathway was upregulated in tumors with high TIL, while the "Hedgehog signaling" and "Wnt signaling" pathways were downregulated.
Molecular SubtypeStromal TILspCR rate n (%)RCB-0/I rateLuminal AHigh------Luminal ALow0/9 (0%)0/9 (0%)Luminal BHigh1/9 (11.1%)1/8 (12.5%)Luminal BLow3/24 (12.5%)6/23 (26.1%)ER+/HER2+High3/9 (33.3%)4/9 (44.4%)ER+/HER2+Low1/6 (16.7%)1/6 (16.7%)ER-/HER2+High8/9 (88.9%)7/7 (100%)ER-/HER2+Low4/8 (50.0%)6/8 (75.0%)Triple NegativeHigh10/19 (52.6%)13/19 (68.4%)Triple NegativeLow7/14 (50.0%)9/13 (69.2%)
Conclusions: We identified genes and gene pathways associated with high TIL expression in breast tumors prior to NAC that provide insight into the interactions between TIL and tumors. TIL can be easily semi-quantitated on H&E and along with these novel biomarkers, may contribute to the personalization of breast cancer therapy.
Citation Format: Moyer AM, Boughey JC, Kalari KR, Suman VJ, McLaughlin SA, Moreno-Aspitia A, Northfelt DW, Gray RJ, Sinnwell JP, Carlson EE, Dockter TJ, Jones KN, Felten SJ, Conners AL, Wieben ED, Ingle JN, Wang L, Weinshilboum RM, Visscher DW, Goetz MP. Differential mRNA expression patterns in breast tumors with high vs. low quantity of stromal tumor–Infiltrating lymphocytes. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-04-05.
Collapse
Affiliation(s)
- AM Moyer
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - JC Boughey
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - KR Kalari
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - VJ Suman
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - SA McLaughlin
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - A Moreno-Aspitia
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - DW Northfelt
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - RJ Gray
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - JP Sinnwell
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - EE Carlson
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - TJ Dockter
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - KN Jones
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - SJ Felten
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - AL Conners
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - ED Wieben
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - JN Ingle
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - L Wang
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - RM Weinshilboum
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - DW Visscher
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - MP Goetz
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| |
Collapse
|
4
|
Boughey JC, Kalari KR, Suman VJ, McLaughlin SA, Moreno Aspitia A, Moyer AM, Northfelt DW, Gray RJ, Vedell PT, Tang X, Dockter TJ, Jones KN, Felten SJ, Conners AL, Hart SN, Visscher DW, Wieben ED, Ingle JN, Hartman AR, Timms K, Elkin E, Jones J, Wang L, Weinshilboum RW, Goetz MP. Abstract P3-07-29: Role of germline BRCA status and tumor homologous recombination (HR) deficiency in response to neoadjuvant weekly paclitaxel followed by anthracycline-based chemotherapy. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-07-29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Both HR deficiency and BRCA mutation status predict response to platinum-based therapy and BRCA mutation status predicts docetaxel resistance. However, the association of either biomarker with response to the individual elements of either AC or taxanes (T) is unknown since T is commonly given concomitantly with or after anthracyclines (A). We evaluated the association of HRD and BRCA mutation status with response to neoadjuvant weekly T followed by AC or (F)EC in high-risk breast cancer.
Methods: We studied 140 high risk Stage I-III breast cancer patients (pts), enrolled in the breast cancer genome guided therapy study (BEAUTY), obtaining biopsies for DNA/RNA sequencing and MRI imaging to assess response to neoadjuvant weekly T (+trastuzumab+/-pertuzumab for HER2+ disease) followed by AC or (F)EC. Germline BRCA status and HR status of tumor samples (Myriad laboratories) were obtained. HR deficient tumor was defined as HRD score ≥42 or BRCA mutation. MRI response by changes in tumor size after 12 weeks of T was classified by WHO criteria. pCR was defined as ypT0/Tis ypN0. Both MRI response after T and pCR (after T and AC) were examined in terms of germline BRCA mutation (gBRCAmut vs. gBRCAwt) and tumor HR deficiency.
Results: Of 140 pts enrolled, 8 withdrew consent and 2 carboplatin treated pts were excluded. Germline data were available for 124/130 pts. 12 patients had BRCA deleterious germline mutations (4 BRCA1, 8 BRCA2). MRI partial (PR)/complete response (CR) rate to T was 47.3% (95% CI: 37.8-57.0%) in the BRCAwt group and 66.7% (95% CI: 34.9-90.1%) in the BRCAmut group. No MRI CR's were observed in BRCA1 mut pts. In contrast, pCR rate was 50% in the 12 gBRCAmut pts (95% CI: 21.1-78.9%) and 31.3% in the 112 gBRCAwt pts (95% CI: 22.8-40.7%). HR deficiency status has thus far been determined for 74 pts: 26 pts have HD deficient tumors: 18 TNBC, 5 Luminal B, 2 ER-/HER2+; and 1 ER+/HER2+. Determination of HR deficiency is ongoing and will be reported for the full cohort in terms of 12 week MRI response to T and pCR to T+AC.
HR deficientMolecular Subtypeyes (%)no (%)TBD (%)Luminal A0/112/11 (18.2)9/11 (81.8)Luminal B5/37 (13.5)13/37 (35.1)19/37 (51.3)Luminal NOS0/21/2 (50)1/2 (50)ER+/Her2+1/17 (5.8)14/17 (82.4)2/17 (11.8)ER-/Her2+2/20 (10)11/20 (55)7/20 (35)Triple Negative18/43 (41.9)6/43 (18.6)17/43 (39.5)germline BRCA statusMRI partial response after T (%)MRI complete response after T (%)pCR after T&AC (%)BRCA11/4 (25)0/42/4 (50)BRCA25/8 (62.5)2/8 (25)4/8 (50)BRCAwt35/112 (31.3)18/112 (16.1)35/112 (31.3)
Conclusion: In the setting of neoadjuvant weekly T followed by AC, pCR rates were non-significantly higher in pts with BRCA1 mutations. While we observed no overall association between BRCA mutation status and response rates to taxanes; nearly all MRI responses to taxanes (partial and complete) were observed in the BRCA2 group. Prospective studies are needed to validate these findings and to determine whether BRCA status can be used to select therapy. HR deficiency is uncommon in luminal A and HER2+, frequent in TNBC, and the association of HRD with both MRI response to taxanes and pCR will be reported at the meeting.
Citation Format: Boughey JC, Kalari KR, Suman VJ, McLaughlin SA, Moreno Aspitia A, Moyer AM, Northfelt DW, Gray RJ, Vedell PT, Tang X, Dockter TJ, Jones KN, Felten SJ, Conners AL, Hart SN, Visscher DW, Wieben ED, Ingle JN, Hartman A-R, Timms K, Elkin E, Jones J, Wang L, Weinshilboum RW, Goetz MP. Role of germline BRCA status and tumor homologous recombination (HR) deficiency in response to neoadjuvant weekly paclitaxel followed by anthracycline-based chemotherapy. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-07-29.
Collapse
Affiliation(s)
- JC Boughey
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - KR Kalari
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - VJ Suman
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - SA McLaughlin
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - A Moreno Aspitia
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - AM Moyer
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - DW Northfelt
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - RJ Gray
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - PT Vedell
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - X Tang
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - TJ Dockter
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - KN Jones
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - SJ Felten
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - AL Conners
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - SN Hart
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - DW Visscher
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - ED Wieben
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - JN Ingle
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - A-R Hartman
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - K Timms
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - E Elkin
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - J Jones
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - L Wang
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - RW Weinshilboum
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| | - MP Goetz
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AR; Mayo Clinic, Jacksonville, FL; Myriad Genetic Laboratories, Salt Lake City, UT
| |
Collapse
|
5
|
Goetz MP, Suman VJ, Reid JM, Northfelt DW, Mahr MA, Dockter T, Kuffel M, Buhrow SA, Safgren SL, McGovern RM, Collins JM, Streicher H, Hawse JR, Haddad TC, Erlichman C, Ames MM, Ingle JN. Abstract PD2-03: Final results of a first-in-human phase I study of the tamoxifen (TAM) metabolite, Z-Endoxifen hydrochloride (Z-Endx) in women with aromatase inhibitor (AI) refractory metastatic breast cancer (MBC) (NCT01327781). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-pd2-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: AI's are more effective than TAM in ER+ breast cancer. In AI refractory MBC, the response rate to TAM is 0% (Osborne 2011). Z-Endx is an active metabolite of TAM and among TAM treated women in the adjuvant and metastatic settings, reduced CYP2D6 metabolism and low Endx concentrations (Css <20 nM) have been associated with increased likelihood of disease recurrence. Preclinical studies have demonstrated greater Z-Endx exposure and anti-tumor activity with oral Z-Endx compared to equivalent doses of oral TAM (Reid 2014)
Methods: We conducted a phase I trial to determine the maximum-tolerated dose (MTD) and evaluate the toxicities, clinical activity, and pharmacokinetics (PK) of Z-Endx in patients (pts) with ER+, AI refractory MBC. Unlimited prior endocrine regimens were allowed. An accelerated titration schedule was applied (2 pts/dose level) until moderate toxicity or DLT, followed by a 3+3 design and then to expansion cohorts (40, 80, and 100 mg/day). Z-Endx was administered orally once daily (28 day cycle). Eye exams were performed at baseline, and end of cycles 2 and 6. PK was performed during cycle 1 and prior to subsequent cycles. For pts in the expansion cohorts, tumor biopsies were obtained at baseline for DNA sequencing (Foundation Medicine). Plasma cholesterol levels were obtained at baseline and after 1 cycle.
Results: From March 2011 to Dec 2014, 41 pts (38 evaluable), median age 60, received Z-Endx once daily encompassing 7 dose levels (20-160 mg/daily). The median number of prior hormonal regimens was 2 and 3 for the dose escalation and expansion cohorts, respectively. Dose escalation was stopped at 160 mg/day given MTD not reached and attainment of mean Endx Css of 3.6 uM. Cycle 1 DLT (PE) was observed in one patient (60 mg). No eye toxicity was observed. PK demonstrated mean Endx Css of > 1 uM at all dose levels ≥ 40 mg/day. Antitumor activity was observed at multiple dose levels including 3 confirmed partial responses and an additional 7 with stable disease for ≥6 cycles. Of these 10 pts, 9 had prior progression on both AI and fulvestrant and 3 additionally on TAM. After 1 cycle, total and LDL cholesterol decreased > 20 points in 54% and 40% of pts, respectively. Tumor sequencing in the expansion cohorts (n=14) did not identify ESR1 mutations; however, ESR1 amplification was identified in 1 pt with prolonged stable disease (>200 days). Of 6 pts with rapid progression (≤2 cycles), 4/6 had either CCND1 amplification (n=1) or at least one of the following activating mutations: ERBB2 L755S (n=1), AKT1 E17K (n=1), MTOR E1799K (n=1).
Conclusions: The direct administration of Z-END provides substantial drug exposure, acceptable toxicity, and "proof of principle" antitumor activity in endocrine resistant MBC. While the MTD was not determined, the goal of achieving Endx Css concentrations of > 1 uM was achieved. Tumor sequencing identified pts with predicted and confirmed endocrine resistance. A randomized phase II comparing endoxifen (80 mg/day) with TAM in AI refractory MBC was recently activated (NCT02311933). Supported in part by CA 133049, CA186686, CA15083, CA116201, and CA15083.
Citation Format: Goetz MP, Suman VJ, Reid JM, Northfelt DW, Mahr MA, Dockter T, Kuffel M, Buhrow SA, Safgren SL, McGovern RM, Collins JM, Streicher H, Hawse JR, Haddad TC, Erlichman C, Ames MM, Ingle JN. Final results of a first-in-human phase I study of the tamoxifen (TAM) metabolite, Z-Endoxifen hydrochloride (Z-Endx) in women with aromatase inhibitor (AI) refractory metastatic breast cancer (MBC) (NCT01327781). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr PD2-03.
Collapse
Affiliation(s)
- MP Goetz
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - VJ Suman
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - JM Reid
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - DW Northfelt
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - MA Mahr
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - T Dockter
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - M Kuffel
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - SA Buhrow
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - SL Safgren
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - RM McGovern
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - JM Collins
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - H Streicher
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - JR Hawse
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - TC Haddad
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - C Erlichman
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - MM Ames
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| | - JN Ingle
- Mayo Clinic, Rochester, MN; National Cancer Institute, Bethesda, MD; Mayo Clinic, Scottsdale, AZ
| |
Collapse
|
6
|
Knutson KL, Kalli KR, Block MS, Hobday TJ, Padley DJ, Erskine CL, Dockter T, Suman VJ, Wilson G, Degnim AC. Abstract P2-11-02: Robust generation of T cell immunity to HER2 in HER2+ breast cancer patients with a degenerate subdominant HLA-DR epitope vaccine. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-11-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Recent studies have indicated that vaccination can protect against cancer development. One key aspect of developing vaccines is circumventing peripheral tolerance by identifying subdominant epitopes that are unique to the deregulated tumor microenvironment. While existing subdominant epitope vaccines are showing efficacy in preventing cancer, these vaccines are applicable only for subsets of patients with specific HLA subtypes. Therefore, we recently developed a degenerate HER2 subdominant epitope-based vaccine that should be useful in approximately 85% of all patients. The vaccine consists of a pool of four HLA-DR-restricted 15-amino acid epitopes (p59, p88, p422, and p885) that are naturally processed and are designed to elicit helper T cell immunity, the cornerstone of immune surveillance. Here we present Phase I trial results of this multi-peptide HER2 vaccine.
Methods: Eligible women had HER2+ breast cancer (Stages II-III) and had completed standard treatment (i.e. surgery, chemotherapy, and trastuzumab) at least 90 days prior to enrollment and were rendered disease free. Vaccine included the above epitope pool along with adjuvant GM-CSF. Patients were vaccinated six times over six months and were monitored for toxicity at each visit. Peripheral blood samples were collected for immune responses evaluating for T cell and antibody immunity. Endpoints were safety and immunogenicity leading to the development CD4 helper T cells that recognized naturally-processed HER2.
Results: Twenty-two subjects (age 33 to 69 years) were enrolled. At the present analysis, 21 have completed all 6 vaccination cycles; one patient withdrew after developing a grade 1 injection site reaction during the first vaccination cycle. Twenty patients have had LVEF measured after vaccination; only 2 patients had an LVEF drop of 10% or more but remained in the normal LEVF range. One severe toxicity was reported: a grade 3 INR increase considered unrelated to treatment. Mild to moderate (grade 1-2) toxicities included injection site reactions, fatigue, and white blood cell count decreases. All patients were alive at analysis and only one experienced a recurrence (median follow-up 507 days, range 22 – 844). Twenty patients have had immune response assessments. Vaccine induced T cell immunity was observed in 94% of patients to p59, in 94% of patients to p88, in 82% of patients to p422, and in 74% of patients to p885. Importantly, T cell immunity to naturally processed HER2 proteins occurred in 94% of patients. The mean number of T cells specific for each peptide, post vaccination, ranged from 349–528 T cells per million peripheral blood mononuclear cells (PBMCs). The mean number of T cells specific for whole HER2 protein was 783 T cells per million PBMCs compared to a mean of 898 T cells/million PBMCs specific for the foreign tetanus toxin. In contrast to T cell responses, modestly increased antibody immunity to HER2 occurred in 35% of patients, consistent with the T cell-inducing design of the vaccine.
Conclusion: Our results show that it is possible to develop vaccines with broad HLA coverage that circumvent natural tolerance and induce tumor antigen-specific immunity in the vast majority of patients.
Citation Format: Knutson KL, Kalli KR, Block MS, Hobday TJ, Padley DJ, Erskine CL, Dockter T, Suman VJ, Wilson G, Degnim AC. Robust generation of T cell immunity to HER2 in HER2+ breast cancer patients with a degenerate subdominant HLA-DR epitope vaccine. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-11-02.
Collapse
Affiliation(s)
- KL Knutson
- Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; TapImmune, Inc., Seattle, WA
| | - KR Kalli
- Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; TapImmune, Inc., Seattle, WA
| | - MS Block
- Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; TapImmune, Inc., Seattle, WA
| | - TJ Hobday
- Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; TapImmune, Inc., Seattle, WA
| | - DJ Padley
- Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; TapImmune, Inc., Seattle, WA
| | - CL Erskine
- Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; TapImmune, Inc., Seattle, WA
| | - T Dockter
- Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; TapImmune, Inc., Seattle, WA
| | - VJ Suman
- Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; TapImmune, Inc., Seattle, WA
| | - G Wilson
- Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; TapImmune, Inc., Seattle, WA
| | - AC Degnim
- Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; TapImmune, Inc., Seattle, WA
| |
Collapse
|
7
|
Goetz MP, Boughey JC, Kalari KR, Eckel-Passow J, Suman VJ, Sicotte H, Hart SN, Moyer AM, Visscher DW, Yu J, Gao B, Sinnwell JP, Mahoney DW, Barman P, Vedell P, Tang X, Thompson K, Dockter TJ, Jones KN, Conners AL, McLaughlin SA, Moreno-Aspitia A, Northfelt DW, Gray RJ, Wieben ED, Farrugia G, Schultz C, Ingle JN, Wang L, Weinshilboum RW. Abstract P1-08-10: Integration of next generation sequencing (NGS) and patient derived xenografts (PDX) to identify novel markers of paclitaxel (T) response in the breast cancer genome guided therapy study (BEAUTY). Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p1-08-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Based upon the association between pathologic response and disease free survival, the neoadjuvant setting is increasingly being used for drug development. NGS has identified unique and recurrent genetic alterations in breast cancer (BC) that are potentially targetable; however, the clinical implications are mostly unknown. We developed a prospective neoadjuvant study (BEAUTY) in high risk BC patients (pts) using weekly T followed by anthracycline-based chemo wherein percutaneous tumor biopsies (PTB) are obtained before/during/after chemo for NGS and PDX. Our goal is to identify novel biomarkers/pathways and develop PDX to test new therapeutic approaches.
Methods: Pts underwent PTB at baseline and after 12 wks of T. Response to T was defined based upon 12 week Ki-67: responder (<15%) vs non-responder (≥15%). Pts with histologic response and absence of invasive BC at 12 wks were classified as responders. NGS was performed using PTB/blood DNA (exome) and PTB (RNA seq). MRI response was classified using RECIST criteria. NGS data were used to identify somatic copy number variants (cnvs) and expressed single nucleotide variants (eSNVs). Non-SCID mice (estrogen supplemented) were implanted ≤ 30 minutes with PTB samples.
Results: Of the first 78 pts, 44 have completed T. Here we focus on 18 pts with either triple negative or luminal B BC. Clinical characteristics according to Ki-67 response are shown in Table 1. Comparison of genomic alterations in BEAUTY pts with TCGA identified a greater overlap with copy number gains (73%) compared to deletions (40%), along with similar observations of mutations in TP53, PTEN, RYR2, and AKT1 genes. Association analysis of CNVs and eSNVs between responders/non-responders identified 33 genes (predominantly located in chromosomes 1, 8, 13) and 580 eSNVs (corresponding to 497 genes) with a p < 0.05. Differential gene expression (DGE) analysis of responders/non-responders identified 198 genes with a p-value < 0.05. Integrated analysis of 539 genes (CNVs, eSNVs and DGE) identified pathways such as TGF-beta, Jak-Stat, WNT and NOTCH signalling. PDX take rate was 44% [triple negative (6/10); Luminal B (2/8)]. PDX growth rate was significantly associated with clinical baseline Ki-67 (p = 0.00014).
Conclusion: This is the first prospective study to demonstrate the feasibility of using PTB to obtain both NGS data and PDX in the neoadjuvant setting. PDX take rate is associated with BC subtype and baseline Ki-67. Studies are ongoing to 1) validate genes/pathways associated with treatment response in subsequent BEAUTY pts; 2) genomically characterize and assess PDX in vivo response to T and 3) Use NGS data to prioritize new drugs/drug combinations in PDX.
Funded by Mayo Clinic Center for Individualized Medicine and MC Cancer Center.
Clinical CharacteristicsOverallResponders: 12 week Ki-67 < 15% (n = 9)Non-Responders: 12 week Ki-67 ≥ 15% (n = 9)Median Age495345T stage T2/T314 (78%)7 (78%)7 (78%)Node Positive8 (44%)4 (44%)4 (44%)Triple negative10 (56%)6 (67%)4 (44%)Luminal B8 (44%)3 (33%)5 (56%)Ki-67 after 12 Weeks of T Median 5% (0-11%)Median 35% (17-60%)Complete/Partial MRI Response after T 6 (67%)2 (22%)
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-08-10.
Collapse
Affiliation(s)
- MP Goetz
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - JC Boughey
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - KR Kalari
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - J Eckel-Passow
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - VJ Suman
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - H Sicotte
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - SN Hart
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - AM Moyer
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - DW Visscher
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - J Yu
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - B Gao
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - JP Sinnwell
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - DW Mahoney
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - P Barman
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - P Vedell
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - X Tang
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - K Thompson
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - TJ Dockter
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - KN Jones
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - AL Conners
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - SA McLaughlin
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - A Moreno-Aspitia
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - DW Northfelt
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - RJ Gray
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - ED Wieben
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - G Farrugia
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - C Schultz
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - JN Ingle
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - L Wang
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| | - RW Weinshilboum
- Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ
| |
Collapse
|